Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20117-2 in Advanced Solid Tumors
NCT07775703Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-20117-2 in solid tumor (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration, Trough Plasma Concentration and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
HS-20117-2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07775703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07775703.